Using sofosbuvir-based direct antiviral agents (DAAs) may accelerate the decline of estimated glomerular filtration rate (eGFR) in patients with chronic hepatitis C virus (HCV) infections, reports a new study.
SER-109, an investigational microbiome drug consisting of a consortium of bacterial spores from healthy donors to prevent recurrent Clostridioides difficile infection (CDI), has shown a favourable safety profile in a phase II trial. Early engraftment of SER-109 dose-species helps reduce the risk of recurrence, although engraftment kinetics suggests a higher dosing to increase efficacy.
Adjuvanted FLU-v, a broad-spectrum influenza vaccine that induces antibodies and cell-mediate immunity, has demonstrated immunogenicity in a phase IIb trial, warranting phase III development to explore its safety and efficacy.
Patients with coronavirus disease 2019 (COVID-19) pneumonia appear to exhibit potential mild pancreatic injury patterns, which may be linked to direct viral involvement of the pancreas or to secondary enzyme abnormalities in the setting of severe illness without extensive pancreatic injury, as reported in a study.
In chronic hepatitis C (CHC) patients, achieving sustained virological response (SVR) after therapy with pegylated interferon with ribavirin (PR) does not reduce the risk of systemic lupus erythematosus (SLE) or rheumatoid arthritis (RA), a recent study has shown.
The novel coronavirus disease (COVID-19) pandemic appears to have a significant impact on oncological care, according to a study, which stresses the need for psycho-oncological support for cancer patients.